Booming Omics in Schistosoma
| Type | Article | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date | 2021-01 | ||||||||||||
| Language | English | ||||||||||||
| Author(s) | Le Govic Yohann1, Gourbal Benjamin2, Boissier Jérôme3 | ||||||||||||
| Affiliation(s) | 1 : Department of Medical Parasitology and Mycology, Amiens University Hospital, Amiens, France 2 : Host–Pathogen Interaction Study Group (GEIHP, EA 3142), UNIV Angers, UNIV Brest, Federative Structure of Research 'Cellular Interactions and Therapeutic Applications', SFR 4208 ICAT, Angers, France 3 : IHPE, University of Montpellier, CNRS, Ifremer, University of Perpignan Via Domitia, Perpignan, France |
||||||||||||
| Source | Trends In Parasitology (1471-4922) (Elsevier BV), 2021-01 , Vol. 37 , N. 1 , P. 6-8 | ||||||||||||
| DOI | 10.1016/j.pt.2020.10.010 | ||||||||||||
| Abstract | Efforts to eliminate schistosomiasis are hindered by incomplete efficacy of the only FDA-approved antischistosomal drug, praziquantel. By using postgenomic technologies, Wendt et al. and Wang et al. deciphered the function of several genes required for worm survival and pathogenesis, which opens the way for the development of innovative parasite-targeted therapies. |
||||||||||||
| Full Text |
|